만성 B형 간염환자에서 간탄력도 측정에 의한 간섬유화의 비침습적 평가 = Non-invasive assessment of liver fibrosis by measuring the Liver stiffness and biochemical markers in chronic hepatitis B patients

국문 초록 (Abstract)

목적: 최근 개발된 간섬유스캔은 비침습적이며 신속하게 간의 탄력도를 측정하여 간섬유화의 정도를 평가하는 진단방법이다. 본 연구는 만성 B형 간염환자에서 간탄력도의 측정이 간섬유화의 평가에 유용한지를 알아 보고자하였으며, 간탄력도와 혈청 간섬유화 표지자들(APRI 및 AST/ALT 비)의 유용성을 비교하였다. 방법: 2005년 3월부터 9월까지 간섬유스캔 검사를 받은 B형 간염환자 228명을 대상으로 하였다. 간조직검사를 시행한 환자 34명의 조직학적인 섬유화의 정도는 Ludwig의 분류에 따라 0단계에서 4단계까지 분류하였다. 결과: 간탄력도는 임상질환별로 비활동성보유자(29명) 7.0±2.7 kPa, 만성간염(106명) 8.3±5.3 kPa, 대상성간경변증(63명) 15.9±8.3 kPa, 비대상성 간경변증(63명) 31.8±20.3 kPa, 간암(4명) 45.1±34.5 kPa이었으며 각 군별로 유의한 차이를 보였다. 간탄력도는 간섬유화의 정도와 유의한 상관관계를 보였다(r=0.726; p<0.001). 간탄력도, APRI 및 AST/ALT 비를 ROC 곡선을 이용하여 비교하였을 때, AUC (area under the curve) 값은 간섬유화 2기 이상에서 각각 0.72, 0.61, 0.58 이었으며, 간섬유화 3기 이상에서 각각 0.92, 0.73, 0.56이었으며, 간섬유화 4기에서 각각 0.97, 0.79, 0.55를 보였다. 간탄력도의 AUC 값이 APRI 및 AST/ALT 비와 비교했을 때 가장 높은 진단적 정확도를 보였다. 결론: 만성 B형 간염환자에서 간섬유스캔으로 측정한 간탄력도는 신속하고 비침습적인 방법으로, 진행된 간질환을 예측할 수 있으며 간섬유화의 정도를 예측하는데 유용하였다.

다국어 초록 (Multilingual Abstract)

Background: Transient elastography (FibroScan(R)) is a rapid and non-invasive method to measure liver stiffness and this allow the assessment of liver fibrosis. The aim of this study was to assess the diagnostic accuracy of measuring the liver stiffness in addition to measuring the other biochemical markers such as the aspartate transaminase to platelet ratio index [APRI] and the AST/ALT ratio. Methods: We enrolled 228 HBsAg positive patients whose liver stiffness was measured by FibroScan(R) between March 2005 and September 2005. Liver biopsy examinations were performed in 34 patients. The fibrosis (F) was staged on a 0-4 scale according to the Ludwig classification. Results: According to the clinical diagnosis, the median values of liver stiffness were 7.0±2.7 kPa for inactive carriers (n=29), 8.3±5.3 kPa for chronic hepatitis patients (n=106), 15.9±8.3 kPa for compensated cirrhosis patients (n=63), 31.8±20.3 kPa for decompensated cirrhosis patients (n=26), and 45.1±34.5 kPa for HCC patients (n=4). The degree of liver stiffness was significantly different between the different disease groups (p<0.001). Liver stiffness was well correlated with the fibrosis stages (r=0.726; p< 0.001). The AUROC of FibroScan(R), the APRI and the AST/ALT ratio values were of the same order; 0.72, 0.61 and 0.58, respectively, for F≥2; 0.92, 0.73, and 0.56, respectively, for F≥3; and 0.97, 0.79, and 0.55, respectively, for F=4. FibroScan(R) offered the best diagnostic performance both for significant fibrosis (F≥2) and severe fibrosis-cirrhosis (F3-F4). Conclusions: FibroScan(R) is a reliable, rapid non-invasive method to diagnose the severity of chronic liver disease and to predict fibrosis in patients with chronic hepatitis B, in addition to using the APRI and AST/ALT ratio. (Korean J Med 72:459-469, 2007)

참고문헌 (Reference)

1 박수영, "임상적으로 간경변증의 증후가 없는 만성 B형 간염에서 간섬유화의 지표로서 AST/ALT 비와 혈소판 수치의 임상적 유용성" 대한소화기학회 43 (43): 246-251, 2004

2 차봉기, "비대상성 간경변증 환자에서 병원감염발생의 위험요소" 대한내과학회 69 (69): 69-75, 2005

3 심성준, "만성 B형 간염 환자에서 중증 간 섬유화 및 간경변의 예측 지표로써 AST/혈소판 비의 유용성" 대한소화기학회 45 (45): 340-347, 2005

4 문원, "라미부딘 내성을 보인 비대상성 간경변증 환자에서 아데포비어의 효과와 안전성; 대상성 간질환군과의 비교" 대한간학회 11 (11): 125-134, 2005

5 김동준, "간섬유증의 약물치료" 7 : 6-11, 2001

6 Giannini E, "Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease" 163 : 218-224, 2003

7 Nishiura T, "Ultrasound evaluation of the fibrosis stage in chronic liver disease by the simultaneous use of low and high frequency probes" 78 : 189-197, 2005

8 Aube C, "Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis" 30 : 472-478, 1999

9 Sandrin L, "Transient elastography: a new noninvasive method for assessment of hepatic fibrosis" 29 : 1705-1713, 2003

10 Friedman SL, "The celluar basis of hepatic fibrosis: mechanism and treatment strategies" 328 : 1828-1835, 1993

11 Arthur MJ, "Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C" 122 : 1525-1528, 2002

12 Castera L, "Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C" 128 : 343-350, 2005

13 Myers RP, "Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B" 39 : 222-230, 2003

14 Poynard T, "Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis(Actitest) in patients with chronic hepatitis C" 3 : 1-8, 2004

15 Fontana RJ, "Noninvasive monitoring of patients with chronic hepatitis C" 36 : 57-64, 2002

16 Ziol M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C" 41 : 48-54, 2005

17 Pilette C, "Non-invasive diagnosis of esophageal varices in chronic liver diseases" 31 : 867-873, 1999

18 Park BK, "Long-term outcome of chronic hepatitis B according to the new histological classification" 6 : 287-300, 2000

19 Bravo AA, "Liver biopsy" 344 : 495-500, 2001

20 Hui AY, "Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model" 100 : 616-623, 2005

21 Shiratori Y, "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy" 132 : 517-524, 2000

22 Nanashima A, "Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection" 48 : 1517-1522, 2003

23 Afdhal NH, "Evaluation of liver fibrosis: a concise review" 99 : 1160-1174, 2004

24 Foucher J, "Diagnosis of cirrhosis by transient elastography (fibroscan): a prospective study" 55 : 403-408, 2006

25 Imbert-Bismut F, "Biochemical markers of liver fibrosis in patients with chronic hepatitis C virus infection: a prospective study" 357 : 1069-1075, 2001

26 Park GJ, "Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?" 15 : 386-390, 2000

27 Perrillo R, "Adefovir difivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus" 126 : 81-90, 2004

28 AASLD, "Accuracy of liver stiffness measurement (LSM) for the diagnosis of cirrhosis in patients with chronic liver disease (CLD): a study in 1345 [Abstract]" 2005

29 Reedy DW, "AST/ALT ratio > or =1 is not diagnostic of cirrhosis in patients with chronic hepatitis C" 43 : 2156-2159, 1998

30 Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C" 38 : 518-526, 2003

31 Cales P, "A novel panel of blood markers to assess the degree of liver fibrosis" 42 : 1373-1381, 2005